Insulet Corp

24 août 2026, 19:56 UTC

Insulet Corp shares are lower amid negative sentiment from two class action lawsuits alleging securities fraud related to product safety concerns.

21 août 2026, 19:56 UTC

Insulet Corp shares are higher today, reflecting positive market momentum. Broader market gains, particularly in cryptocurrency, contribute to the stock's upward movement.

20 août 2026, 23:11 UTC

Insulet Corp shares are trading lower in after-market hours, continuing a decline that follows a reversal from earlier highs. No specific news was identified.

19 août 2026, 23:01 UTC

Insulet Corp shares are higher in after-market trading, continuing a trend of gains over the last three sessions without any specific news driving the movement.

18 août 2026, 20:03 UTC

Insulet Corp's shares are higher today, having previously peaked before pulling back. The stock has advanced since Monday's close, despite no specific news.

17 août 2026, 20:06 UTC

Insulet Corp shares are lower amid a class action lawsuit alleging securities law violations related to safety risks in manufacturing processes.

14 août 2026, 20:06 UTC

Insulet Corp faces a securities fraud class action lawsuit from Levi & Korsinsky, LLP, contributing to a decline in shares during regular trading hours.

13 août 2026, 23:06 UTC

Insulet Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains near the middle of its one-month range.

12 août 2026, 19:36 UTC

Insulet Corp shares are higher during Wednesday's session, recovering from earlier lows. Broader market inflation data may be supporting positive sentiment.

11 août 2026, 19:46 UTC

Insulet Corp's shares are higher, continuing a four-session trend, despite no specific news. Market participants are reacting to recent economic indicators and Fed rate expectations.

10 août 2026, 22:56 UTC

Insulet Corp shares are lower in after-market trading following a class action lawsuit from Pomerantz LLP alleging false statements about manufacturing practices and product safety.

7 août 2026, 19:36 UTC

Insulet Corp shares are higher as Deutsche Bank initiates coverage with a "buy" rating and a $190 price target, despite a downgrade from Oppenheimer.

6 août 2026, 23:32 UTC

Insulet Corp shares are lower in after-market hours following a downgrade to Market Perform by Leerink Partners and a reduced price target of $145.

5 août 2026, 23:46 UTC

Insulet Corp. shares traded lower in after-market hours, reflecting routine activity and cautious market sentiment amid disappointing private sector employment data.

4 août 2026, 23:56 UTC

Insulet Corp shares are lower in after-market hours, showing little change since Tuesday's close amid a lack of specific company news.

3 août 2026, 19:36 UTC

Insulet Corp's shares are higher today, supported by a positive trend in the medical devices sector. The stock remains above its 20-day moving average.

31 juil. 2026, 20:06 UTC

Insulet Corp shares are declining amid a securities class action lawsuit alleging misrepresentations about the safety of its Omnipod products.

29 juil. 2026, 18:43 UTC

Insulet Corp shares are higher, driven by gains in the Health Care Equipment sub-sector. The stock remains well above its 20-day moving average.

28 juil. 2026, 19:06 UTC

Insulet Corp shares are trading higher, benefiting from a significant rise in the Health Care Equipment sub-sector and ongoing momentum above their 20-day moving average.

27 juil. 2026, 20:06 UTC

Insulet Corp shares are higher today, reflecting broader market trends despite an earlier pullback from a session high. No specific news was identified.

24 juil. 2026, 22:26 UTC

Insulet Corp shares are lower in after-market hours, following a decline from earlier session lows. No specific company news was identified to explain the movement.

22 juil. 2026, 20:01 UTC

Insulet Corp shares are lower amid a class action lawsuit alleging securities fraud related to safety claims about its Omnipod products.

20 juil. 2026, 18:36 UTC

Insulet Corp is gaining today after being identified as a healthcare stock likely to deliver sustainable market-beating returns, despite ongoing legal challenges.